Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Biogen stock (BIIB)

Buy Biogen stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Biogen
NASDAQ: BIIB-USD
About two hours ago

$224.53

+$2.95 (+1.33%)

Biogen is a drug manufacturers - general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Biogen employs 7,570 staff and has a trailing 12-month revenue of around $9.7 billion.

Our top picks for where to buy Biogen stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $10,000 cash
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for Investing by theme

Go to site
Earn up to $300 on new deposits
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

How to buy Biogen stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BIIB. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Biogen stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $10,000 cash
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
OPTO
Not rated yet
OPTO
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
Cash App
Finder Score: 3 / 5: ★★★★★
Cash App
★★★★★
Stocks, ETFs, Cryptocurrency
$0
$0
4.5%
N/A
Buy and sell over 1,800 stocks and ETFs commission-free and for as little as $1.
Moomoo
Finder Score: 4.3 / 5: ★★★★★
Exclusive
Moomoo
★★★★★
Stocks, Options, ETFs
$0
$0
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Public.com
Finder Score: 4.2 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
5.1%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Biogen stock price (NASDAQ: BIIB)

Use our graph to track the performance of BIIB stocks over time.

Biogen shares at a glance

Information last updated 2024-07-12.
Latest market close$221.58
52-week range$189.44 - $281.12
50-day moving average $225.82
200-day moving average $232.87
Wall St. target price$281.57
PE ratio 29.6
Dividend yield N/A (0%)
Earnings per share (TTM) $8.00

Is it a good time to buy Biogen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biogen price performance over time

Historical closes compared with the close of $221.58 from 2024-07-15

1 week (2024-07-09) -3.27%
1 month (2024-06-14) -4.36%
3 months (2024-04-16) 13.54%
6 months (2024-01-16) -10.00%
1 year (2023-07-14) -20.56%
2 years (2022-07-15) 2.11%
3 years (2021-07-16) 324.62
5 years (2019-07-16) 231.55

Is Biogen stock undervalued or overvalued?

Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biogen's P/E ratio

Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 30x. In other words, Biogen shares trade at around 30x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Biogen's PEG ratio

Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Biogen's EBITDA

Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.5 billion.

The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.

Biogen financials

Revenue TTM $9.7 billion
Operating margin TTM 27.28%
Gross profit TTM $7.9 billion
Return on assets TTM 4.86%
Return on equity TTM 8.05%
Profit margin 12.07%
Book value $104.49
Market Capitalization $34.5 billion

TTM: trailing 12 months

Biogen share dividends

We're not expecting Biogen to pay a dividend over the next 12 months.

Have Biogen's shares ever split?

Biogen's shares were split on a 3:1 basis on 17 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.

Biogen share price volatility

Over the last 12 months, Biogen's shares have ranged in value from as little as $189.44 up to $281.12. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is -0.038. This would suggest that Biogen's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Biogen has bucked the trend.

Biogen overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc. ; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.

Frequently asked questions

null
What percentage of Biogen is owned by insiders or institutions?
Currently 0.158% of Biogen shares are held by insiders and 93.159% by institutions.
How many people work for Biogen?
Latest data suggests 7,570 work at Biogen.
When does the fiscal year end for Biogen?
Biogen's fiscal year ends in December.
Where is Biogen based?
Biogen's address is: 225 Binney Street, Cambridge, MA, United States, 02142
What is Biogen's ISIN number?
Biogen's international securities identification number is: US09062X1037
What is Biogen's CUSIP number?
Biogen's Committee on Uniform Securities Identification Procedures number is: 449370105

More guides on Finder

Ask a Question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site